People who took Zepbound, Eli Lilly’s weight loss drug, shed more pounds than those on Novo Nordisk’s Wegovy in a clinical ...

Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...

A new study is out that compares the effectiveness of two popular weight loss drugs, Wegovy and Zepbound. The study, which ...

State measures now seek to remove barriers to weight-loss drugs, as demand for the meds skyrockets amid rising concerns about ...

Gastric balloons are not new as a weight-loss aid, and stationary balloons filled with saline have long been approved for ...

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...

WEDNESDAY, Dec. 4, 2024 (HealthDay News) -- Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly.

Clinical trials have shown that people using weight-loss jabs, such as Wegovy and Mounjaro, lose anywhere between 16% and 21% ...

Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.

Weight loss drugs such as Ozempic and Wegovy are increasingly popular among adults, who have flocked to the new medication as an alternative to the traditional - and often ineffective - advice to "eat ...

Ozempic, Wegovy, and other weight-loss drugs could make millions healthier, but access and affordability barriers abound.